Olema Pharmaceuticals, Inc.

NasdaqGS OLMA

Olema Pharmaceuticals, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -3.11

Olema Pharmaceuticals, Inc. Price to Earnings Ratio (P/E) is -3.11 on January 14, 2025, a 63.51% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Olema Pharmaceuticals, Inc. 52-week high Price to Earnings Ratio (P/E) is -2.93 on January 13, 2025, which is 5.84% above the current Price to Earnings Ratio (P/E).
Olema Pharmaceuticals, Inc. 52-week low Price to Earnings Ratio (P/E) is -12.31 on February 12, 2024, which is -295.72% below the current Price to Earnings Ratio (P/E).
Olema Pharmaceuticals, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -7.73.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGS: OLMA

Olema Pharmaceuticals, Inc.

CEO	Dr. Sean P. Bohen M.D., Ph.D.
IPO Date	Nov. 19, 2020
Location	United States
Headquarters	512 2nd Street
Employees	74
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Key trends

Past 5 years